Celgene (NASDAQ:CELG) had its target price reduced by equities researchers at Stifel Nicolaus from $149.00 to $130.00 in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 20.50% from the company’s previous close.
Several other analysts have also weighed in on CELG. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene in a report on Monday, August 28th. Vetr cut shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price target on the stock. in a research note on Tuesday, August 29th. BTIG Research reissued a “neutral” rating on shares of Celgene in a research note on Tuesday, September 5th. Cowen reissued a “buy” rating and set a $150.00 price target on shares of Celgene in a research note on Tuesday, September 12th. Finally, Bank of America reissued a “buy” rating on shares of Celgene in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. Celgene currently has a consensus rating of “Buy” and an average target price of $135.59.
Shares of Celgene (CELG) opened at $107.88 on Friday. The firm has a market cap of $84,940.00, a P/E ratio of 16.92, a PEG ratio of 0.84 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene has a fifty-two week low of $94.55 and a fifty-two week high of $147.17.
In other Celgene news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.95% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Beacon Capital Management acquired a new stake in shares of Celgene during the fourth quarter worth $0. Capital Counsel LLC NY raised its holdings in shares of Celgene by 0.4% during the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 6 shares during the period. Diversified Trust Co raised its holdings in shares of Celgene by 0.4% during the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 9 shares during the period. Arete Wealth Advisors LLC raised its holdings in shares of Celgene by 0.3% during the third quarter. Arete Wealth Advisors LLC now owns 3,106 shares of the biopharmaceutical company’s stock worth $325,000 after acquiring an additional 10 shares during the period. Finally, Fort Pitt Capital Group LLC raised its holdings in shares of Celgene by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 11 shares during the period. 79.84% of the stock is currently owned by institutional investors.
WARNING: “Celgene (CELG) PT Lowered to $130.00 at Stifel Nicolaus” was first published by American Market News and is owned by of American Market News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/22/celgene-celg-pt-lowered-to-130-00-at-stifel-nicolaus.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
